Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. (Q54945635)

13 June 2018

title

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. (English)

1 reference

13 June 2018

1 reference

1 reference

8

1 reference

13 June 2018

Paolo Antonio Ascierto

6

P A Ascierto

1 reference

13 June 2018

M Gillet

20

0 references

Evgeny V Levchenko

E Levchenko

3

0 references

Jochen Utikal

J Utikal

5

0 references

Licia Rivoltini

L Rivoltini

2

0 references

author name string

R Gutzmer

1

1 reference

13 June 2018

A Testori

4

1 reference

13 June 2018

L Demidov

7

1 reference

13 June 2018

R Ridolfi

9

1 reference

13 June 2018

D Schadendorf

10

1 reference

13 June 2018

P Queirolo

11

1 reference

13 June 2018

A Santoro

12

1 reference

13 June 2018

C Loquai

13

1 reference

13 June 2018

B Dreno

14

1 reference

13 June 2018

A Hauschild

15

1 reference

13 June 2018

E Schultz

16

1 reference

13 June 2018

T P Lesimple

17

1 reference

13 June 2018

N Vanhoutte

18

1 reference

13 June 2018

B Salaun

19

1 reference

13 June 2018

S Jarnjak

21

1 reference

13 June 2018

P M De Sousa Alves

22

1 reference

13 June 2018

J Louahed

23

1 reference

13 June 2018

V G Brichard

24

1 reference

13 June 2018

F F Lehmann

25

1 reference

13 June 2018

publication date

8 August 2016

1 reference

13 June 2018

full work available at URL

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070281

0 references

published in

ESMO Open

1 reference

13 June 2018

volume

1

1 reference

13 June 2018

issue

4

1 reference

13 June 2018

page(s)

e000068

1 reference

13 June 2018

Updates in Therapy for Advanced Melanoma

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Pembrolizumab versus Ipilimumab in Advanced Melanoma

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Integrated NY-ESO-1 antibody and CD8 T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Final version of 2009 AJCC melanoma staging and classification

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Ex vivo characterization of polyclonal memory CD8 T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Identification of promiscuous KIF20A long peptides bearing both CD4 and CD8 T-cell epitopes: KIF20A-specific CD4 T-cell immunity in patients with malignant tumor.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

T-helper-1-cell cytokines drive cancer into senescence

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Prevalence and prognostic and predictive relevance of PRAME in breast cancer

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

Detection and functional analysis of CD8 T cells specific for PRAME: a target for T-cell therapy

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

MAGE-A3 is a frequent tumor antigen of metastasized melanoma

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5070281

10.1136/ESMOOPEN-2016-000068

13 August 2018

Identifiers

DOI

1 reference

13 June 2018

PMC publication ID

5070281

1 reference

13 June 2018

PubMed publication ID

27843625

1 reference

13 June 2018